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We investigated whether bone marrow or peripheral blood stem cells from older sibling donors or cord blood
from unrelated donors provided a better outcome in allogeneic hematopoietic stem cell transplantation for
relatively older patients who were candidates for myeloablative conditioning. Clinical outcomes of 97 patients
aged 45 years or older with hematologic malignancies who received unrelated cord blood transplantation
(CBT) (n ¼ 66) or bone marrow transplantation (BMT) or peripheral blood stem cell transplantation (PBSCT)
from related donors (n ¼ 31) were compared. The cumulative incidences of grades III to IV acute and
extensive chronic graft-versus-host diseases were similar between both groups. Although transplant-related
mortality was signiﬁcantly lower after CBT compared with BMT/PBSCT from related donors (hazard ratio [HR],
.29, P ¼ .04), overall mortality (HR, .72, P ¼ .47) and relapse (HR, 2.02, P ¼ .23) were not signiﬁcantly different
after CBT and BMT/PBSCT from related donors. These data suggest that CBT could be as safe and effective as
BMT/PBSCT from older related donors for relatively older patients when it is used as a primary unrelated stem
cell source.
 2014 American Society for Blood and Marrow Transplantation.INTRODUCTION demonstrated similar survival, relapse, and TRM between
Donor age has been associated with transplant outcomes
in allogeneic hematopoietic stem cell transplantation (allo-
HSCT) after myeloablative conditioning or reduced-intensity
conditioning (RIC) [1-5]. Older donor age resulted in an
increased incidence of severe graft-versus-host disease
(GVHD), which led to higher transplant-related mortality
(TRM) or overall mortality after allo-HSCT from unrelated
adult donors [1,2]. In contrast, it is difﬁcult to determine the
exact effect of the age of related donors, because increasing
recipient age is frequently accompanied by increased donor
age after allo-HSCT from related donors. However, older
donor age of related donors may also be associated with
adverse outcomes [3-5].
Several studies, including ours, comparing both cord
blood transplantation (CBT) and bone marrow transplan-
tation (BMT)/peripheral blood stem cell transplantation
(PBSCT) from unrelated donors after myeloablative condi-
tioning in adult patients demonstrated that the incidence of
severe GVHD was signiﬁcantly lower after CBT than after
unrelated BMT/PBSCT. The survival rate and relapse inci-
dence in CBT recipients were comparable with those in un-
related BMT/PBSCT recipients [6-9]. Moreover, we alsoedgments on page 1154.
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14.04.005unrelated CBT and related BMT/PBSCT (rBMT/PBSCT) reci-
pients [10]. The incidences of grades III to IV acute GVHD
(aGVHD) and extensive chronic GVHD (cGVHD) among CBT
recipients were also signiﬁcantly lower than those among
rBMT/PBSCT recipients. Because the lower risk of severe
GVHD is one of the most attractive advantages of CBT, the use
of cord blood instead of bone marrow or mobilized periph-
eral blood as a stem cell source might offer the possibility of
decreasing severe GVHD in older patients. However, there
has been no comparative study between CBT and BMT/PBSCT
from older related donors after myeloablative conditioning
in relatively older patients.
We previously reported that unrelated CBT after mye-
loablative conditioning is feasible in patients over the age of
45 years [11,12]. In this retrospective study, we report on a
clinical comparison of CBT from unrelated donors and BMT/
PBSCT from older related donors in patients older than
45 years of age with hematologic malignancies who were
candidates for a myeloablative conditioning.
METHODS
Patients and Transplant Procedures
This retrospective study included 97 consecutive patients, 45 years of
age or older, who received CBT (n ¼ 66) from unrelated donors or BMT
(n ¼ 26) or PBSCT (n ¼ 5) from related donors for acute myeloid leukemia
(AML), myelodysplastic syndrome (MDS), chronic myeloid leukemia (CML),
acute lymphoblastic leukemia (ALL), and non-Hodgkin lymphoma (NHL) at
the Institute of Medical Science, University of Tokyo between May 1992
and July 2013. Nineteen patients who received rBMT/PBSCTand 32 patients
who received CBT were included from our previous study with extendedTransplantation.
Table 1
Characteristics of Patients, Grafts, and Transplantation
Characteristic rBMT/PBSCT CBT P
Number of patients 31 66
Recipient age, yr, median (range) 48 (45-58) 49 (45-55) .60
Recipient sex, n (%) .51
Male 20 (64) 37 (56)
Female 11 (35) 29 (43)
Recipient CMV serostatus, n (%) .18
Positive 28 (90) 64 (96)
Negative 0 (0) 2 (3)
Unknown 3 (9) 0 (0)
Disease type, n (%) .08
AML 16 (51) 44 (66)
MDS 2 (6) 8 (12)
CML 6 (19) 3 (4)
ALL 3 (9) 8 (12)
NHL 4 (12) 3 (4)
Disease status at transplantation,* n (%) .48
Standard 8 (25) 23 (34)
High 23 (74) 43 (65)
Conditioning regimen, n (%) <.01
TBI12GyþAra-C/G-CSF 21 (64) 0 (0)
TBI12GyþAra-C/G-CSFþCY 2 (6) 52 (78)
TBI12GyþAra-C/G-CSFþFlu 0 (0) 3 (4)
TBI12GyþCY 3 (9) 3 (4)
TBI12GyþAra-CþCY 1 (3) 8 (12)
TBI12GyþVP16 4 (12) 0 (0)
GVHD prophylaxis, n (%) .23
Cyclosporine Aþmethotrexate 29 (93) 65 (98)
Cyclosporine A 2 (6) 1 (1)
Number of nucleated cells, 107/kg, median (range) 26.6 (3.13-50.0)z 2.39 (1.72-5.07) <.01
Number of CD34þ cells, 105/kg, median (range) 40.5 (20.6-75.0)x 1.04 (.17-3.15) <.01
Donor age, yr, median (range) 46.5 (38-58) d d
Sex compatibility, n (%) .81
Female donor to male recipient 8 (25) 20 (30)
Other 23 (74) 46 (69)
HLA disparities,y n (%) <.01
0 28 (90) 1 (1)
1 2 (6) 13 (19)
2 1 (3) 52 (78)
ABO incompatibility, n (%) .04
Match 19 (61) 20 (30)
Major mismatch 4 (12) 17 (25)
Minor mismatch 5 (16) 18 (27)
Bidirectional mismatch 3 (9) 11 (16)
Time from diagnosis to transplantation, days, median (range) 521 (59-2501) 390.5 (55-6783) .84
<365 d, n (%) 12 (38) 31 (46) .51
365 d, n (%) 19 (61) 35 (53)
Year of transplantation, n (%) <.01
1992-2002 27 (87) 17 (25)
2003-2013 4 (12) 49 (74)
Follow-up for survivors, mo, median (range) 185 (32-258) 87 (4-175) <.01
CMV indicates cytomegalovirus; CY, cyclophosphamide; Flu, ﬂudarabine; VP-16, etoposide.
* Disease status at transplantation was classiﬁed as standard risk or high risk; CR1 or CR2 without poor prognostic karyotype for AML and ALL, refractory
anemia for MDS, chronic phase for CML, and CR1 or CR2 for NHL were classiﬁed as standard risk, whereas patients in all other situations were classiﬁed as high
risk.
y Number of HLA disparities deﬁned as low resolution for HLA-A, -B, and -DR.
z Number of nucleated cells was only for BMT recipients.
x Number of CD34þ cells was only for PBSCT recipients.
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complete remission (CR1) or second complete remission (CR2) without
poor prognostic karyotype for AML and ALL, refractory anemia for MDS,
chronic phase for CML, and CR1 or CR2 for NHL were classiﬁed as standard
risk, whereas patients in all other situations were classiﬁed as high risk.
Although bone marrow or mobilized peripheral blood from HLA-
compatible related donors within immediate families is a frontline graft
source, patients without a suitable closely HLA-compatible related donor
were eligible for CBT as an alternative ﬁrst treatment option, unless they had
any type of anti-HLA antibody. Cord blood units were obtained from the
Japan Cord Blood Bank Network and were selected as reported previously
[9,10]. All patients received 12 Gy total body irradiation (TBI)-based mye-
loablative conditioning regimens, and cyclosporine-based GVHD pro-
phylaxis regimens, as previously reported [9,10]. For myeloid disease,
granulocyte colony-stimulating factor (G-CSF) was added to the condition-
ing regimen to increase the susceptibility to cytosine arabinoside (Ara-C)through induction of cell cycle entry of dormant leukemia cells, as previ-
ously reported [10]. Almost all patients received some supportive care, such
as antibacterial, antifungal and antiviral agents, as previously reported
[9,10]. The institutional review board of the Institute of Medical Science,
University of Tokyo approved this study, which was conducted in accor-
dance with the Declaration of Helsinki.End Points and Deﬁnitions
The primary study end point was overall survival (OS), which was
deﬁned as the time from the date of transplantation to the date of death or
last contact. Secondary end points were relapse, TRM, GVHD, and neutrophil
and platelet recovery. Relapse was deﬁned by morphologic evidence of
disease in peripheral blood, bone marrow, or extramedullary sites. TRMwas
deﬁned as death during a remission. Both aGVHD and cGVHD were graded
according to previously published criteria [13,14]. The incidence of aGVHD
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was evaluated in engrafted patients surviving more than 100 days.
Neutrophil engraftment was deﬁned as the ﬁrst of 3 consecutive days during
which the absolute neutrophil count was at least .5  109/L. Platelet
engraftment was deﬁned as the ﬁrst of 7 consecutive days with a platelet
count of 20  109/L or higher without platelet transfusion.
Statistical Analysis
Baseline patient and transplant characteristics were compared using
the chi-square test for categorical variables and the Mann-Whitney U test
for continuous variables. The probability of OS was estimated according to
the Kaplan-Meier method, and groups were compared using Cox regres-
sion models or the log-rank test. The probabilities of relapse, TRM, aGVHD
and cGVHD, and neutrophil and platelet engraftment were estimated based
on a cumulative incidence method to accommodate competing risks.
Multivariate analysis was performed with a Cox proportional hazard model
adjusted for OS and a Fine and Gray proportional hazards model for the
others. In addition to the stem cell source (CBT versus rBMT/PBSCT), the
following variables were considered: disease type (myeloid [AML, MDS,
CML] versus lymphoid [ALL, NHL] disease), disease status at transplantation
(standard risk versus high risk), time from diagnosis to transplantation
(<365 days versus 365 days), sex compatibility between donor and
recipient (female donor to male recipient versus other), ABO compatibility
between donor and recipient (match versus mismatch), and year of
transplantation (1992 to 2002 versus 2003 to 2013).
All statistical analyses were performed with EZR (Saitama Medical
Center, Jichi Medical University, Saitama, Japan), a graphic user interface for
R 3.0.2 (R Foundation for Statistical Computing, Vienna, Austria) [15].
P < .05 was considered signiﬁcant. Analysis of data was performed in
December 2013.
RESULTS
Characteristics of Patients and Grafts
The characteristics of patients, grafts, and transplant
procedures are summarized in Table 1. Recipients’ age, sex,
cytomegalovirus serostatus, disease type, disease status at
transplantation, GVHD prophylaxis, sex incompatibility be-
tween donors and recipients, and time from diagnosis toTable 2
Univariate and Multivariate Analysis of Transplant Outcomes after rBMT/





HR (95% CI) P HR (95% CI) P
Neutrophil engraftment
rBMT/PBSCT vs. CBT .69 (.38-1.04) .07 .46 (.26-.81) <.01
Platelet engraftment
rBMT/PBSCT vs. CBT .30 (.14-.61) <.01 .24 (.12-.50) <.01
Grades III-IV aGVHD
rBMT/PBSCT vs. CBT .57 (.18-1.85) .36 .53 (.15-1.90) .34
Extensive cGVHD
rBMT/PBSCT vs. CBT 1.01 (.53-1.91) .97 1.08 (.49-2.35) .84
Overall mortality
rBMT/PBSCT vs. CBT .69 (.36-1.32) .26 .72 (.30-1.73) .47
Relapse
rBMT/PBSCT vs. CBT 1.42 (.52-3.87) .49 2.02 (.63-6.42) .23
TRM
rBMT/PBSCT vs. CBT .38 (.16-.93) .03 .29 (.08-.99) .04
* For neutrophil engraftment, lymphoid disease was also a signiﬁcant
variable (HR, 2.40; 95% CI, 1.52 to 3.79; P < .01). For platelet engraftment,
lymphoid disease was also a signiﬁcant variable (HR, 1.74; 95% CI, 1.17 to
2.59; P< .01). For grades III-IV aGVHD, ABO incompatibility was a signiﬁcant
variable (HR, 4.41; 95% CI, 1.06 to 18.24; P¼ .04). For extensive cGVHD, high
risk of disease status at transplantation was a signiﬁcant variable (HR, 3.14;
95% CI, 1.39 to 7.09; P< .01). For overall mortality, high risk of disease status
at transplantation (HR, 3.33; 95% CI, 1.36 to 8.11; P < .01) and ABO in-
compatibility (HR, 3.14; 95% CI, 1.44 to 6.87; P < .01) were signiﬁcant var-
iables. For relapse, high risk of disease status at transplantation was a
signiﬁcant variable (HR, 4.55; 95% CI, 1.08 to 19.23; P¼ .03). For TRM, female
donor to male recipient (HR, 2.89; 95% CI, 1.11 to 7.52; P ¼ .02) and ABO
incompatibility (HR, 5.20; 95% CI, 1.56 to 17.33; P < .01) were also signiﬁ-
cant variables.transplantation were almost the same between the CBT and
rBMT/PBSCT recipients. On the other hand, there were
signiﬁcant differences in the following variables (Table 1).
The conditioning regimen signiﬁcantly differed between
the CBT and rBMT/PBSCT recipients (P < .01). The most
common conditioning regimen was TBI12GyþAra-C/G-
CSFþcyclophosphamide (78%) for CBT and TBI12GyþAra-C/
G-CSF (64%) for rBMT/PBSCT. The number of nucleated cells
or CD34þ cells for CBT recipients was 1 log lower than in
rBMT or rPBSCT recipients, respectively. The proportion of
HLA disparity and ABO incompatibility was higher among
CBT recipients than rBMT/PBSCT recipients. CBT was more
frequently performed in recent years, resulting in the
signiﬁcantly shorter follow-up period for CBTcompared with
that for rBMT/PBSCT. Median follow-up was 185 months
(range, 32 to 258 months) for rBMT/PBSCT recipients and
87 months (range, 4 to 175 months) for CBT recipients
(P < .01).Neutrophil and Platelet Engraftment
One patient in the CBT group died on day 21 due to en-
cephalitis, and 1 patient in the rBMT/PBSCT group died on
day 7 due to organ failure. Primary graft failure occurred in 3
of the surviving 65 patients in the CBT group, but there was
no primary graft failure in the rBMT/PBSCT group. As ex-
pected, neutrophil recovery was signiﬁcantly delayed after
CBT as compared with rBMT/PBSCT. Median times to
neutrophil recovery were 22 days (range, 18 to 34 days) after
CBT, as compared with 18 days (range, 11 to 40 days) after
rBMT/PBSCT (P < .01). The cumulative incidence of neutro-
phil recovery on day 60 was slightly lower after CBT (93.9%;
95% conﬁdence interval [CI], 83.5% to 97.9%) compared with
rBMT/PBSCT (96.8%; 95% CI, 57.8% to 99.8%) (P ¼ .07). In the
multivariate analysis, the hazard risk of neutrophil engraft-
ment was signiﬁcantly lower after CBT as compared with
rBMT/PBSCT (hazard ratio [HR], .46; 95% CI, .26 to .81; P< .01,
Table 2).
Platelet recovery was also signiﬁcantly delayed after CBT
as compared with rBMT/PBSCT. Median times to platelet
recovery were 42 days (range, 13 to 104 days) after CBT, as
compared with 24 days (range, 15 to 300 days) after rBMT/
PBSCT (P < .01). The cumulative incidence of platelet recov-
ery on day 100 was signiﬁcantly lower after CBT (90.8%; 95%
CI, 80.0% to 95.9%) compared with rBMT/PBSCT (93.5%; 95%
CI, 71.5% to 98.7%) in the univariate analysis (P < .01); the
difference was also signiﬁcant in multivariate analyses (HR,
.24; 95% CI, .12 to .50; P < .01, Table 2).Acute and Chronic GVHD
The cumulative incidences of grades II to IV (HR, .90; 95%
CI, .49 to 1.64; P ¼ .76) and grades III to IV aGVHD (HR, .53;
95% CI, .15 to 1.90; P ¼ .34) were similar between CBT and
rBMT/PBSCT recipients inmultivariate analyses (Table 2). The
unadjusted cumulative incidence of grades III to IV aGVHD at
100 days was 9.2% (95% CI, 3.7% to 17.8%) in CBT recipients
and 16.1% (95% CI, 5.7% to 31.2%) in rBMT/PBSCT recipients
(P ¼ .35). Extensive cGVHD developed in 27 of 58 CBT
recipients and in 13 of 27 rBMT/PBSCT recipients surviving
more than 100 days. In a multivariate analysis, the cumula-
tive incidences of cGVHD (HR, .94; 95% CI, .55 to 1.62; P¼ .84)
and extensive cGVHD (HR, 1.08; 95% CI, .49 to 2.35; P ¼ .84)
were similar between CBT and rBMT/PBSCT recipients in
multivariate analysis (Table 2).
Table 3
Cause of Death









Primary disease 0 2 5 12
GVHD 0 0 5 5
Infection 1 2 4 2
Organ failure 1 0 0 0
Figure 1. Outcomes after CBT or BMT/PBSCT from related donors in patients
aged 45 years or older with hematologic malignancies after a myeloablative
conditioning regimen. Adjusted probability of OS (A), unadjusted cumulative
incidence of relapse (B), and TRM (C).
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The adjusted probabilities of OS at 5 years were 67.4%
(95% CI, 55.7% to 81.6%) for recipients of CBT and 55.2% (95%
CI, 39.4% to 77.4%) for recipients of rBMT/PBSCT (Figure 1A).
In multivariate analysis, the hazard risk of overall mortality
was similar between CBT and rBMT/PBSCT recipients (HR,
.72; 95% CI, .30 to 1.73; P¼ .47; Table 2).We also compared OS
of both groups for each disease risk. However, OS of both
recipient groups was also equivalent in standard-risk pa-
tients (n ¼ 31) and high-risk patients (n ¼ 66) (data not
shown). The unadjusted cumulative incidence of relapse at
5 years was 22.0% (95% CI, 12.7% to 33.0%) in CBT recipients
and 16.7% (95% CI, 5.9% to 32.3%) in rBMT/PBSCT recipients
(P ¼ .48) (Figure 1B). In multivariate analysis, the hazard risk
for relapse was similar between CBT and rBMT/PBSCT re-
cipients (HR, 2.02; 95% CI, .63 to 6.42; P ¼ .23; Table 2). The
unadjusted cumulative incidence of TRM was signiﬁcantly
lower after CBT at 100 days (3.0%; 95% CI, .6% to 9.4%) and
5 years (15.8%; 95% CI, 7.6% to 26.6%) compared with rBMT/
PBSCT at 100 days (6.5%; 95% CI, 1.1% to 18.9%) and 5 years
(32.7%; 95% CI, 16.8% to 49.6%) (P ¼ .04) (Figure 1C). In
multivariate analysis, the hazard risk of TRM was signiﬁ-
cantly lower after CBT as compared with rBMT/PBSCT (HR,
.29; 95% CI, .08 to .99; P ¼ .04; Table 2).
We also analyzed a subgroup of patients aged 50 years or
older after CBT (n ¼ 29) and rBMT/PBSCT (n ¼ 11). In
multivariate analysis, the hazard risk of overall mortality
(HR, .36, P ¼ .10) and relapse (HR, 2.73, P ¼ .41) after CBT was
comparable with that after rBMT/PBSCT, respectively. How-
ever, the hazard risk of TRM was lower after CBT than after
rBMT/PBSCT (HR, .16; 95% CI, .04 to .56; P < .01).
The causes of death before and after 100 days after
transplantation by donor type are summarized in Table 3.
The major cause of death in both recipient groups was pri-
mary disease. However, GVHD and infection as a primary
cause of latemortality weremore common after rBMT/PBSCT
compared with CBT.DISCUSSION
The objective of this study was to compare the transplant
outcomes after CBT and rBMT/PBSCT in relatively older
patients who were candidates for myeloablative condition-
ing. Unexpectedly, there were no signiﬁcant differences in
aGVHD and cGVHD between CBT and rBMT/PBSCT recipients.
However, TRM was higher after rBMT/PBSCT compared with
CBT. The reduced TRM in CBT might be in part due to
improved supportive care, because CBT was more frequently
performed in recent years. However, year of transplantation
did not affect any clinical results in our multivariate analysis.
On the other hand, we used almost the same 12-Gy TBI-
based myeloablative conditioning and cyclosporine-based
GVHD prophylaxis regimens during the period for both
recipients of CBT and rBMT/PBSCT. Among relatively older
T. Konuma et al. / Biol Blood Marrow Transplant 20 (2014) 1150e11551154patients who were candidates for such myeloablative con-
ditioning, survival and relapse were not signiﬁcantly dif-
ferent after CBT and rBMT/PBSCT.
Whether an older sibling donor or unrelated donor
should be chosen as an optimal donor is an important
question in allo-HSCT for older patients. There have been
some clinical comparisons of allo-HSCT from older sibling
donors and unrelated donors in older patients [16-18]. A
European Group for Blood and Marrow Transplantation
analysis by Kröger et al. [16] reported on comparisons of allo-
HSCT from older sibling donors and young unrelated donors
in 719 patients older than 50 years with MDS. They showed
that recipients from young unrelated donors had improved
survival compared with those from older sibling donors
among older patients with MDS. A single-institute analysis
by Ayuk et al. [17] showed similar outcomes from older
sibling donors compared with young unrelated donors
among older patients with AML in CR. On the other hand,
Alousi et al. [18] of the Center for International Blood and
Marrow Transplantation also performed a similar study in
2172 patients older than 50 years with leukemia or lym-
phoma. In contrast, their data showed that the risks of overall
mortality, relapse, and TRM were lower after allo-HSCT from
older sibling donors compared with those from young un-
related donors. However, comparative clinical outcomes of
CBT and BMT/PBSCT from older related donors after mye-
loablative conditioning have yet to be clariﬁed. Our data
showed comparable outcomes for CBT and BMT/PBSCT from
older related donors after myeloablative conditioning in
relatively older patients when cord blood was selected as a
primary unrelated donor source.
In comparison with other sources of allo-HSCT, the lower
risk of GVHD without compromised graft-versus-leukemia
effects is one of the most important advantages of CBT. In
our study, the incidences of severe aGVHD and cGVHD were
not signiﬁcantly different after CBT and rBMT/PBSCT. Relapse
was also similar between CBT and rBMT/PBSCT recipients.
However, TRM was signiﬁcantly lower after CBT compared
with that after rBMT/PBSCT. GVHD-associated mortality was
a common cause of late death after rBMT/PBSCT compared
with CBT. Newell et al. [19] reported a shorter duration and a
higher response of cGVHD to systemic immunosuppressive
treatment in CBT recipients than in BMT/PBSCT recipients,
suggesting that a longer duration of systemic immunosup-
pressive treatment for cGVHD might have contributed to
higher infection-related late mortality after rBMT/PBSCT
compared with CBT. In fact, we previously reported that the
termination of immunosuppressive treatment for rBMT/
PBSCT recipients was slower than those for CBT recipients
[10]. These effects might have contributed to higher TRM
after rBMT/PBSCT compared with CBT in our study. In addi-
tion, the absence of risk for donors may also be one of the
most attractive advantages of CBT for older patients. Older
patients generally have older donors as well when they have
an HLA-compatible sibling. Because older donors are more
likely to have organ dysfunction or comorbidity, older pa-
tients hardly ever ﬁnd healthy sibling donors. These prob-
lems could be overcome with the advantages of CBT,
especially in older patients.
Myeloablative conditioning regimens for allo-HSCT have
been restricted to younger patients and those without
comorbidities, because TRM occurs more frequently among
older patients and those with serious comorbidities. RIC
regimens have recently been expanded for use with graft
sources not only from bone marrow or mobilized peripheralblood but also from cord blood. Although the risk of graft
failure after CBT has been reported to be higher after RIC
compared with myeloablative conditioning [20], several re-
ports showed similar survival with acceptable engraftment
between CBT and other graft sources from related and un-
related adult donors after RIC [21,22]. Further studies are
warranted to establish optimal RIC regimens for CBT.
In conclusion, our data showed that CBT had almost
equivalent results compared with rBMT/PBSCT after mye-
loablative conditioning for relatively older patients. Howev-
er, these results should be interpreted with caution because
this study was a retrospective single-institute analysis that
included a heterogeneous population and a relatively small
number of patients. In addition, although our study was
performed in patients older than 45 years of age, it should be
noted that most patients were younger than 55 years of age.
This is because the patients in our cohort received myeloa-
blative conditioning, which often excludes even older pa-
tients. As such, our results cannot be extended to patients
older than 60 years of age until another similar study is
performed using RIC in those older than 55 years. Although
these ﬁndings should be conﬁrmed in larger prospective
studies, CBTcould be as safe and effective as BMT/PBSCT from
older related donors after myeloablative conditioning for
relatively older patients when it is used as a primary unre-
lated stem cell source.
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